Introduction: Why dsRNA Detection Matters in mRNA Therapeutics

The rapid evolution of mRNA vaccine and therapeutic technologies has transformed the landscape of modern biopharmaceuticals. As global production expands, double-stranded RNA (dsRNA) has emerged as a critical quality control parameter during in vitro transcription (IVT) of mRNA.

Even trace amounts of dsRNA byproducts can trigger innate immune responses, activating pathways like TLR3, MDA5, and RIG-I, which in turn affect mRNA translation efficiency, safety, and potency. Accurate and sensitive detection of dsRNA impurities is therefore essential for ensuring the purity, stability, and immunogenicity control of mRNA drug substances (DS) and drug products (DP).

In response to these challenges, Hzymes Biotech has launched two powerful detection platforms — the Double-Stranded RNA (dsRNA) ELISA Kit and the RIG-I dsRNA Quantification Kit — designed to deliver comprehensive, high-precision dsRNA analysis across multiple application scenarios.

Hzymes dsRNA ELISA Kit: Stable, Accurate, and Sensitive

High-Performance Immunoassay for dsRNA Quantification

Performance Overview

Scientific Rationale Behind Hzymes’ Design

Unlike kits using poly(I:C) as the standard, Hzymes developed high-purity, randomly sequenced dsRNA standards that more accurately reflect the physicochemical properties of true dsRNA impurities. By pairing these standards with optimized antibody combinations, the kit delivers precise quantification unaffected by dsRNA sequence length or modification type.

Applications

• mRNA drug substance (DS) QC
• In-process control during IVT
• Regulatory compliance for WHO, CDE, and USP guidelines
• Comparative analysis of modified nucleotide systems (UTP, pUTP, 5-OMe-UTP, N1-Me-pUTP)

RIG-I dsRNA Quantification Kit: Direct Immunogenicity Evaluation

From Detection to Functional Assessment

While ELISA provides accurate quantification, immunogenicity evaluation requires functional insight. The Hzymes RIG-I dsRNA Quantification Kit offers a biochemical approach to evaluate dsRNA immunogenicity based on RIG-I receptor activation — a key step in antiviral immune signaling.

When RIG-I binds dsRNA, it triggers ATP hydrolysis, converting ATP into ADP and inorganic phosphate. This ATPase activity directly correlates with dsRNA content and immunogenic potential, allowing users to evaluate biological relevance beyond mere concentration measurement.

Product Highlights

Key Advantages

• Direct Immunogenicity Assessment — evaluates receptor activation, not just dsRNA quantity.
• High Sensitivity for Short RNA Fragments — ideal for evaluating short-chain dsRNA impurities often overlooked by other assays.
• Complementary to ELISA — use both kits for a full spectrum of dsRNA characterization (quantitative + functional).

Dual-System Workflow: From Quantification to Immunogenicity

By integrating both kits, mRNA manufacturers and research teams can achieve quantitative precision and functional validation — ensuring their mRNA vaccines and therapeutics meet the highest standards of purity and safety.

Conclusion: Redefining dsRNA Detection Standards

As mRNA-based drug development accelerates, precision quality control becomes indispensable. Hzymes’ dsRNA ELISA Kit and RIG-I dsRNA Quantification Kit form a powerful, complementary toolkit that bridges the gap between analytical quantification and biological assessment.

With high stability, superior specificity, and advanced receptor-based detection, Hzymes continues to empower the global biopharmaceutical community — ensuring every mRNA product is safer, purer, and more effective.